Sangamo BioSciences | SGMO - Interest Income


Sangamo BioSciences reported $2.8M in Interest Income for its fiscal quarter ending in June of 2023.





Interest Income Change Date
Alnylam Pharmaceuticals USD 26.6M 32K Mar/2026
Bayer EUR 169M 39M Dec/2025
BioCryst Pharmaceuticals USD -0.13 3.59M Dec/2024
Biogen USD 37.9M 700K Mar/2026
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Compugen USD 1.14M 185K Dec/2025
CSL USD 18M 1000K Dec/2024
Gilead Sciences USD 95M 0 Mar/2026
GlaxoSmithKline GBP 22M 96M Mar/2026
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
J&J USD 2.27 0.13 Jun/2026
Karyopharm Therapeutics USD -0.15 0.11 Dec/2024
Merck USD 35M 34M Mar/2026
Pfizer USD -0.04 115M Jun/2026
Sanofi EUR 77M 17M Jun/2026
Sarepta Therapeutics USD 7M 1.74M Mar/2026
Tectonic Therapeutic USD 1.74M 217K Dec/2024
Ultragenyx Pharmaceutical USD 6M 512K Mar/2026
Vertex Pharmaceuticals USD 120.6M 5.8M Jun/2026